Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30116349 | 0.96 | OPRM1 (0.50) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL31683327 | 0.96 | OPRM1 (0.50) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL30287602 | 0.93 | OPRM1 (0.58) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL30533415 | 0.93 | OPRM1 (0.53) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL30116353 | 0.90 | OPRM1 (0.60) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL29379978 | 0.89 | OPRD1 (0.55) | OPRM1OPRD1 | |
| SCHEMBL31121205 | 0.89 | OPRD1 (0.55) | OPRM1OPRD1 | |
| SCHEMBL30533416 | 0.89 | SLC6A2 (0.56) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL30503062 | 0.89 | OPRM1 (0.58) | OPRM1OPRD1SLC6A2 | |
| SCHEMBL29390272 | 0.89 | SLC6A2 (0.51) | OPRM1OPRD1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4316528-A1 | NOVEL IMMUNOACTIVE INTERLEUKIN 2 ANALOG CONJUGATE AND METHOD FOR PREPARING SAME | Hanmi Pharm. Co., Ltd. (KR) | 2024-02-07 | — | — | EP | disclosed |
| CN-116419765-A | GLP-1/GIP dual agonists, long acting conjugates thereof and pharmaceutical compositions comprising the same | 韩美药品株式会社 | 2023-07-11 | — | — | CN | disclosed |
| CN-116390769-A | Pharmaceutical composition for preventing or treating lupus-related diseases comprising glucagon/GLP-1/GIP triple agonist or long-acting conjugate thereof | 韩美药品株式会社 | 2023-07-04 | — | — | CN | disclosed |
| CN-115916238-A | Hyperlipemia preventing or treating composition containing glucagon/GLP-l/GIP receptor triple agonist or conjugate thereof and use method thereof | 韩美药品株式会社 | 2023-04-04 | — | — | CN | disclosed |
| CN-115811970-A | Liquid formulations of long-acting conjugates of glucagon, GLP-1 and GIP triple agonists | 韩美药品株式会社 | 2023-03-17 | — | — | CN | disclosed |
| CN-115803015-A | Liquid formulations of long-acting conjugates of glucagon derivatives | 韩美药品株式会社 | 2023-03-14 | — | — | CN | disclosed |
| CN-115776880-A | Liquid preparation | 韩美药品株式会社 | 2023-03-10 | — | — | CN | disclosed |
| CN-115697375-A | Pharmaceutical composition comprising GLP-2 derivatives or long-acting conjugates thereof for the prevention or treatment of mucositis induced by radiotherapy, chemotherapy or a combination thereof | 韩美药品株式会社 | 2023-02-03 | — | — | CN | disclosed |